HAMBURG, Germany --Sequenom, a transnational pharmacogenomics technology company headquartered here, completed a $37 million financing round through equity funding last week. Participants in the round included Nomura International, Deutsche Bank, Haspa Bank, Euroventures, Vertex Capital, Alafi Capital, and Value Management and Research. Previous investors, including Techno Venture Management, Alpinvest International, Global Life Sciences, Dresdner Kleinwort Benson, and SR One, also participated.
Hubert Koster, Sequenom's president and CEO, said the funding will enable the company to complete full commercial launch of its proprietary DNA analysis products and to expand its manufacturing, sales, and service support structure.
By year's end, the company said it will launch its DNA MassArray Basic System, a modular, semiautomated platform that includes an array mass spectrometer, nanoplotter, and bioinformatics workstation, and its DNA MassArray APL system, which offers robotics and software to meet high-throughput demands in industrial settings.